In order to assess the effectiveness of treating EGFR TKI-resistant NSCLC cell lines with FAK TKIs, we utilized two EGFR wild-type cell lines (A549, H1299) with known insensitivity to EGFR TKIs [34], as well as the EGFR mutant cell line H1975, with acquired EGFR TKI resistance due to a T790M mutation in the EGFR gene [35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.